1832 Asset Management’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
– Sell
-13,050
Closed -$272K – 785
2021
Q3
$272K Sell
13,050
-81,950
-86% -$1.75M ﹤0.01% 632
2021
Q2
$2.02M Sell
95,000
-208,800
-69% -$4.22M ﹤0.01% 424
2021
Q1
$5.94M Sell
303,800
-139,296
-31% -$2.87M 0.01% 346
2020
Q4
$8.8M Buy
443,096
+8,696
+2% +$161K 0.02% 297
2020
Q3
$7.67M Hold
434,400
– – 0.02% 283
2020
Q2
$7.72M Buy
434,400
+149,400
+52% +$2.56M 0.02% 257
2020
Q1
$4.31M Buy
285,000
+159,066
+126% +$2.6M 0.02% 310
2019
Q4
$2.2M Buy
125,934
+45,934
+57% +$754K 0.01% 378
2019
Q3
$1.21M Hold
80,000
– – ﹤0.01% 419
2019
Q2
$1.34M Buy
+80,000
New +$1.32M ﹤0.01% 446

Other funds holding HQL

1832 Asset Management's HQL Position: Q4 2021 in Review

1832 Asset Management sold out of abrdn Life Sciences Investors (HQL) in Q4 2021, closing a stake of 13,050 shares — an estimated $272K sold.

1832 Asset Management first reported a position in HQL in Q2 2019 and held it in 10 quarters. The position peaked at $8.8M in Q4 2020. 67 funds tracked by Wall St. Rank hold HQL as of Q4 2021.

  • 1832 Asset Management reported no remaining abrdn Life Sciences Investors position as of Q4 2021 after selling out during the quarter.
  • 1832 Asset Management sold 13,050 abrdn Life Sciences Investors shares in Q4 2021, an estimated $272K.
  • 1832 Asset Management first reported a position in abrdn Life Sciences Investors in Q2 2019 and held it in 10 quarters.
  • 1832 Asset Management's abrdn Life Sciences Investors position peaked at $8.8M in Q4 2020.
  • 67 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2021.

Based on 1832 Asset Management's 13F filing for Q4 2021, filed 15 Feb 2022.